WO1981001102A1 - Remede pour le traitement des infections virales de l'oeil et d'autres organes - Google Patents

Remede pour le traitement des infections virales de l'oeil et d'autres organes Download PDF

Info

Publication number
WO1981001102A1
WO1981001102A1 PCT/DE1979/000123 DE7900123W WO8101102A1 WO 1981001102 A1 WO1981001102 A1 WO 1981001102A1 DE 7900123 W DE7900123 W DE 7900123W WO 8101102 A1 WO8101102 A1 WO 8101102A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral
viral infections
eye
bacterial
Prior art date
Application number
PCT/DE1979/000123
Other languages
German (de)
English (en)
Inventor
A Romano
Original Assignee
A Romano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Romano filed Critical A Romano
Priority to EP79901504A priority Critical patent/EP0039325A1/fr
Priority to PCT/DE1979/000123 priority patent/WO1981001102A1/fr
Priority to DD79216966A priority patent/DD147005A5/de
Priority to IT28000/79A priority patent/IT1126570B/it
Publication of WO1981001102A1 publication Critical patent/WO1981001102A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the invention relates to an agent for the treatment of viral infections of the eye and other organs.
  • Antiviral substances such as interferon have been used to treat viral infections of the eye (Emödi et al., 1974, Jordan, 1974). An improvement in the viral infections was generally achieved, but in many cases a recurrence of an acute viral infection could not be prevented.
  • the aim of the invention is an agent for the treatment of viral infections of the eye and other organs, both for preventive treatment and for the treatment of acute infections, such as those e.g. can be caused by the herpes simplex virus or the adenovirus, which enables effective prophylactic treatment and rapid and very effective control of acute viral infections.
  • the invention proposes an agent for the treatment of viral infections of the eye and other organs from antiviral substance, adjuvants and vehicle, which is characterized in that it also contains, if necessary in the form of a separate preparation, a known antibiotic or several known antibiotics.
  • the agent of the invention enables effective and rapid control of viral infections. It has been found in the context of the invention that there is a very close connection between a bacterial infection and a viral disease, ie that a viral disease is always a bacterial infection or a viral disease is accompanied by such a bacterial infection.
  • bacterial enzymes are present in the focus of the disease. These bacterial enzymes, such as hyaluronidase, impair or prevent the formation of antiviral interferon in the cell, which enables the virus to penetrate and spread.
  • a bacterial infection can be determined in addition to a viral infection and thus the beginning of a viral disease using the following method:
  • the method consists of staining a glucose aminoglycan substrate with toluidine blue (an orthochromatic color) and then decolourising it, thereby obtaining a halo (lightened area) at the reaction site between the substrate and the decomposing enzyme.
  • glucosaminoglycan substrate e.g. Chondroitin sulfate
  • hyaluronidic acid in concentrations of 0.001 °. to 0.11.
  • control plates are prepared:
  • PBS Phoshate Buffer Saline
  • Microplates the Hank material with agarose and the substrate and in addition the standard enzymes hyaluronidase (auferg dertestes) (1 mg / ml or solutions according to a standard card, at one place on the plate.
  • hyaluronidase erythyluronidase
  • a filter paper such as a disc, e.g. the strip for de: or the usual disc for an antibiogram micro capillary tubes.
  • a filter paper such as a disc, e.g. the strip for de: or the usual disc for an antibiogram micro capillary tubes.
  • Components of the agent 1. For local treatment (drops or ointment),
  • Antibiotics Gentamycin sulfate or
  • antibiotics are used for ophthalmic treatment.
  • the amounts used correspond to the usual, but still need to be effective (bak ⁇ terizide minimum effect). In general, the amounts used vary between 3 mcg / ml and 100 mcg / ml.
  • Neomycin sulfate in particular supports the interferon and facilitates its penetration.
  • Metals such as silver, copper, mercury and iodine.
  • Zinc Oxide 0.5% in saline is given.
  • N-acetylcysteine another form of the cysteine group, is also recommended as an interferon stabilizer.
  • Human fibroblastic interferon for local application in a dosage of 1x10 ref units / ml 2 to 6x / day for at least 7 days. It is a saline solution of phosphate buffer (pH 7), which also contains a solution of human albumin (0.3%).
  • Poly I C (polylysine-CA cellulose), dissolved in phosphate buffer (pH 7) in a dosage of 1000 mcg / ml, is stored in a cooling system, for local application 100 to 200 units / 0.1 cm 3 6 to Administered 8x / day for at least 7 days (total therapeutic dose of 5000 to 30000 mcg). A total therapeutic dose of 30 mcg / 70 kg body weight is administered for intravenous use (that is 4000 to 6000 units in 24 hours).
  • the neutralizers listed above should be used a few minutes before the administration of Poly I: C in order to achieve depolarization of the tissue. This depolarization prepares the intrusion of interferon.
  • N-Acetylcysteindextran 0.05 ml / drop.
  • Steroids for local use 0.05% to 0.5% to 1%, 4x / day, for general use 5 to 50 mg / day.
  • the method is required to detect the onset of a viral disease and to begin effective treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le remede pour le traitement des infections virales de l'oeil et d'autres organes a partir de substance antivirale, d'adjuvants et vehicules, renferme en outre un ou plusieurs antibiotiques connus, le cas echeant dans une preparation separee. Les infections bacteriennes presentes a cote des infections virales, seront ainsi combattues grace a l'antibiotique, empechant ainsi la formation d'enzymes bacteriens, comme l'hyaluronidase, qui inhibent la formation d'interferon dans la cellule. La presence d'une infection bacterienne avant et/ou pendant une infection virale peut etre mise en evidence par la presence d'enzymes bacteriens avant et pendant la maladie virale.
PCT/DE1979/000123 1979-10-19 1979-10-19 Remede pour le traitement des infections virales de l'oeil et d'autres organes WO1981001102A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP79901504A EP0039325A1 (fr) 1979-10-19 1979-10-19 Remede pour le traitement des infections virales de l'oeil et d'autres organes
PCT/DE1979/000123 WO1981001102A1 (fr) 1979-10-19 1979-10-19 Remede pour le traitement des infections virales de l'oeil et d'autres organes
DD79216966A DD147005A5 (de) 1979-10-19 1979-11-16 Verfahren zum nachweis bakterieller infektionen
IT28000/79A IT1126570B (it) 1979-10-19 1979-12-07 Prodotto per il trattamento di infezioni virali dell'occhio e di altri organi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WODE79/00123 1979-10-19
PCT/DE1979/000123 WO1981001102A1 (fr) 1979-10-19 1979-10-19 Remede pour le traitement des infections virales de l'oeil et d'autres organes

Publications (1)

Publication Number Publication Date
WO1981001102A1 true WO1981001102A1 (fr) 1981-04-30

Family

ID=6699862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1979/000123 WO1981001102A1 (fr) 1979-10-19 1979-10-19 Remede pour le traitement des infections virales de l'oeil et d'autres organes

Country Status (4)

Country Link
EP (1) EP0039325A1 (fr)
DD (1) DD147005A5 (fr)
IT (1) IT1126570B (fr)
WO (1) WO1981001102A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080032A2 (fr) * 1981-11-20 1983-06-01 Enzo Biochem, Inc. Préparation pharmaceutique pour le traitement de lésions herpétiques

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091245A (en) * 1963-12-09 1967-11-15 Pfizer & Co C Method for inducing resistance to viral infections in an animal
DE1617498A1 (de) * 1965-12-28 1969-10-23 Glaxo Lab Ltd Verfahren zur Herstellung einer Nukleinsaeuresubstanz
DE2056294A1 (de) * 1969-11-17 1971-07-15 Glaxo Laboratories Ltd, Greenford Middlesex (Großbritannien) Verfahren zur Herstellung antiviraler zweistrangiger Ribonucleinsäuren
FR2134292A1 (en) * 1971-04-30 1972-12-08 Inst Nat Sante Rech Med Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
DE2437166A1 (de) * 1974-08-01 1976-02-19 Helmut Prof Dr Med Stickl Antivirales arzneimittel auf der grundlage eines heterologen interferon-inducers
DE2650608A1 (de) * 1975-11-07 1977-05-18 Beecham Group Ltd Arzneipraeparat zur behandlung von mastitis bei milchvieh
DE2725204A1 (de) * 1976-06-04 1977-12-22 Merieux Inst Immunitaets-stimulierendes medikament und verfahren zu seiner herstellung
DE2902136A1 (de) * 1978-01-22 1979-08-09 Ashida Shin Interferon und es enthaltende zubereitungen
EP0004770A2 (fr) * 1978-04-11 1979-10-17 Efamol Limited Composition pharmaceutique et diététique comprenant des acides gamma-linoléniques

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091245A (en) * 1963-12-09 1967-11-15 Pfizer & Co C Method for inducing resistance to viral infections in an animal
DE1617498A1 (de) * 1965-12-28 1969-10-23 Glaxo Lab Ltd Verfahren zur Herstellung einer Nukleinsaeuresubstanz
DE2056294A1 (de) * 1969-11-17 1971-07-15 Glaxo Laboratories Ltd, Greenford Middlesex (Großbritannien) Verfahren zur Herstellung antiviraler zweistrangiger Ribonucleinsäuren
FR2134292A1 (en) * 1971-04-30 1972-12-08 Inst Nat Sante Rech Med Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
DE2437166A1 (de) * 1974-08-01 1976-02-19 Helmut Prof Dr Med Stickl Antivirales arzneimittel auf der grundlage eines heterologen interferon-inducers
DE2650608A1 (de) * 1975-11-07 1977-05-18 Beecham Group Ltd Arzneipraeparat zur behandlung von mastitis bei milchvieh
DE2725204A1 (de) * 1976-06-04 1977-12-22 Merieux Inst Immunitaets-stimulierendes medikament und verfahren zu seiner herstellung
DE2902136A1 (de) * 1978-01-22 1979-08-09 Ashida Shin Interferon und es enthaltende zubereitungen
EP0004770A2 (fr) * 1978-04-11 1979-10-17 Efamol Limited Composition pharmaceutique et diététique comprenant des acides gamma-linoléniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Band 72, Nummer 9, 2. Marz 1970, (Columbus, Ohio US) A. BILLIAU et al.: "Induction of the interferon mechanism by singlestranded RNA; potentiation by polybasic substances", siehe Seite 236, Zusammenfassung Mr. 41333r, Proc.Soc. Exp.Biol.Med.1969, 132(2), 790-796 (Eng.) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080032A2 (fr) * 1981-11-20 1983-06-01 Enzo Biochem, Inc. Préparation pharmaceutique pour le traitement de lésions herpétiques
EP0080032A3 (fr) * 1981-11-20 1985-11-13 Enzo Biochem, Inc. Préparation pharmaceutique pour le traitement de lésions herpétiques

Also Published As

Publication number Publication date
IT7928000A0 (it) 1979-12-07
IT1126570B (it) 1986-05-21
DD147005A5 (de) 1981-03-11
EP0039325A1 (fr) 1981-11-11

Similar Documents

Publication Publication Date Title
DE2832204A1 (de) Mittel zur behandlung von nervenerkrankungen, verfahren zu seiner herstellung und seine verwendung
DE60009146T2 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
Chang et al. Quantitative cytochemical studies of RNA in experimental mercury poisoning. I. Changes in RNA content
DE2047368A1 (de) Verfahren zur Herstellung von 9 (beta D Arabinofuranosyl) adenin 5 phos phat
EP0095682A2 (fr) Procédé de préparation de produits régénérateurs de cellules et de tissus
DE1695976C3 (de) 4-Hydroxy-1-β-D-ribofuranosyltetrahydro-2(1H)-pyrimidinon, Verfahren zu seiner Herstellung und seine Verwendung
DE2024586B2 (de) Langsame a - und ß - Glykoproteine aus Mikrobenkörpern, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
EP0602686A2 (fr) Concentrés des lectines d'extraits de gui et compositions standardisées, stabilisées des lectines de gui correspondantes, procédé pour leur préparation, ainsi que médicaments les contenant et leur utilisation
DE68907392T2 (de) Dysmnesie modifizierende Arzneimittel.
DE68903065T2 (de) Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien.
EP0017867B1 (fr) Préparation pharmaceutique stimulant la prolifération des cellules hépatiques et facteur de protection et de croissance du foie
WO1981001102A1 (fr) Remede pour le traitement des infections virales de l'oeil et d'autres organes
DE602004006024T2 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
DE2538573A1 (de) Uridine und diese enthaltende pharmazeutische praeparate
DE2605576C3 (de) Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten
DE2234832C2 (de) Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate
DE69918953T2 (de) Zusammensetzung von oligosacchariden zur regulierung von apoptose
DE3141970C2 (fr)
DE69118926T2 (de) Antivirale Fraktion von einem wässerigen Extrakt von Lentinus edodes
EP1096947B1 (fr) Medicament topique pour le traitement d'infections virales
DE3410848C2 (de) Verwendung von Flunarizin zur Behandlung von Tumoren
DE2528460A1 (de) Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE60111571T2 (de) Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
DE3249215T1 (de) Verfahren zur herstellung von humanem (gamma)-interferon
DE60219770T2 (de) Krebsmittel

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): BR DK JP SU US

AL Designated countries for regional patents

Designated state(s): AT CH DE FR GB LU NL SE